Skip to main content
Erschienen in: Pneumo News 5/2021

20.10.2021 | Pneumonie | Fortbildung Zur Zeit gratis

Wichtiges für die Akutsituation und die Nachsorge

Pneumonie und COVID-19 bei COPD-Patienten

verfasst von: Regina Steuder, Hendrik Pott, Michael Maxheim, Prof. Dr. Bernd Schmeck

Erschienen in: Pneumo News | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Auszug

Die Pneumonie gehört zu den weltweit häufigsten infektiologischen Krankheitsbildern. Die andauernde Coronavirus-Pandemie hat diesen Umstand noch verschärft. Da Menschen der besonders betroffenen Altersgruppen auch häufig unter COPD leiden, fassen wir im Artikel wichtige Aspekte der Prophylaxe, Diagnostik und Therapie für diese Patientengruppe zusammen.
Literatur
1.
Zurück zum Zitat Welte T et al. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71-9 Welte T et al. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71-9
2.
Zurück zum Zitat Ewig S et al. [Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (OGP), the Austrian Society for Infectious and Tropical Diseases (OGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie. 2021; https://doi.org/10.1055/a-1497-0693 Ewig S et al. [Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (OGP), the Austrian Society for Infectious and Tropical Diseases (OGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie. 2021; https://​doi.​org/​10.​1055/​a-1497-0693
3.
Zurück zum Zitat Eurich DT et al. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597-604 Eurich DT et al. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597-604
4.
Zurück zum Zitat Zeb MS et al. Follow Up Chest Radiograph in Community Acquired Pneumonia (CAP) - Are We Meeting the Standards? Am J Resp Crit Care. 2019;199 Zeb MS et al. Follow Up Chest Radiograph in Community Acquired Pneumonia (CAP) - Are We Meeting the Standards? Am J Resp Crit Care. 2019;199
5.
Zurück zum Zitat Forstner C et al. Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia. Chest. 2020;157(3):529-39 Forstner C et al. Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia. Chest. 2020;157(3):529-39
6.
Zurück zum Zitat Mullerova H et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124-33 Mullerova H et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124-33
7.
Zurück zum Zitat GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602
8.
Zurück zum Zitat GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706 GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706
9.
Zurück zum Zitat von der Lippe E et al. Gesundheitsbedingte Einschränkungen bei alltäglichen Aktivitäten in Deutschland. J Health Monit. 2017;2(3):89-96 von der Lippe E et al. Gesundheitsbedingte Einschränkungen bei alltäglichen Aktivitäten in Deutschland. J Health Monit. 2017;2(3):89-96
10.
Zurück zum Zitat GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133-61 GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133-61
11.
Zurück zum Zitat Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931-40 Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931-40
12.
Zurück zum Zitat Miravitlles M et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075 Miravitlles M et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075
13.
Zurück zum Zitat Bertrams W et al. Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Sci Rep. 2020;10(1):241 Bertrams W et al. Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Sci Rep. 2020;10(1):241
14.
Zurück zum Zitat Jung AL et al. Surface Proteome of Plasma Extracellular Vesicles as Biomarkers for Pneumonia and Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Infect Dis. 2020;221(2):325-35 Jung AL et al. Surface Proteome of Plasma Extracellular Vesicles as Biomarkers for Pneumonia and Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Infect Dis. 2020;221(2):325-35
15.
Zurück zum Zitat Liapikou A et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J. 2012;39(4):855-61 Liapikou A et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J. 2012;39(4):855-61
16.
Zurück zum Zitat Bornheimer R et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS One. 2017;12(10):e0184877 Bornheimer R et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS One. 2017;12(10):e0184877
17.
Zurück zum Zitat Aliberti S et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res. 2014;15:27. Aliberti S et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res. 2014;15:27.
18.
Zurück zum Zitat Walters JA et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3:CD006897 Walters JA et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3:CD006897
19.
Zurück zum Zitat Chan KPF et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020;171:106085 Chan KPF et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020;171:106085
21.
Zurück zum Zitat McAuley H et al. COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD. ERJ Open Res. 2021;7(1):00718-2020 McAuley H et al. COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD. ERJ Open Res. 2021;7(1):00718-2020
22.
Zurück zum Zitat Zhou F et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62 Zhou F et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62
23.
Zurück zum Zitat Lowe KE et al. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med. 2021;181(5):709-11 Lowe KE et al. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med. 2021;181(5):709-11
24.
Zurück zum Zitat Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. Front Med (Lausanne). 2020;7:627278 Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. Front Med (Lausanne). 2020;7:627278
25.
Zurück zum Zitat Pardhan S et al. The Risk of COVID-19 Related Hospitalsation, Intensive Care Unit Admission and Mortality in People With Underlying Asthma or COPD: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:668808 Pardhan S et al. The Risk of COVID-19 Related Hospitalsation, Intensive Care Unit Admission and Mortality in People With Underlying Asthma or COPD: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:668808
26.
Zurück zum Zitat Gerayeli FV et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789 Gerayeli FV et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789
27.
Zurück zum Zitat Lommatzsch M et al. [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie. 2021;75(1):19-30 Lommatzsch M et al. [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie. 2021;75(1):19-30
28.
Zurück zum Zitat Sen P et al. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry. PLoS One. 2021;16(6):e0252576 Sen P et al. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry. PLoS One. 2021;16(6):e0252576
29.
Zurück zum Zitat Idzko M et al. [Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (OGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]. Pneumologie. 2021;75(6):418-20 Idzko M et al. [Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (OGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]. Pneumologie. 2021;75(6):418-20
30.
Zurück zum Zitat Malin JJ et al. Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). Infection. 2021; https://doi.org/10.1007/s15010-021-01645-2 Malin JJ et al. Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). Infection. 2021; https://​doi.​org/​10.​1007/​s15010-021-01645-2
31.
Zurück zum Zitat Halpin DMG, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(1):24-36 Halpin DMG, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(1):24-36
32.
Zurück zum Zitat Aggarwal AN et al. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest. 2006;130(5):1454-61 Aggarwal AN et al. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest. 2006;130(5):1454-61
33.
Zurück zum Zitat van Doremalen N et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7 van Doremalen N et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7
34.
Zurück zum Zitat Group RC et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704 Group RC et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704
Metadaten
Titel
Wichtiges für die Akutsituation und die Nachsorge
Pneumonie und COVID-19 bei COPD-Patienten
verfasst von
Regina Steuder
Hendrik Pott
Michael Maxheim
Prof. Dr. Bernd Schmeck
Publikationsdatum
20.10.2021
Verlag
Springer Medizin
Schlagwörter
Pneumonie
COPD
COVID-19
Erschienen in
Pneumo News / Ausgabe 5/2021
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI
https://doi.org/10.1007/s15033-021-2749-1

Weitere Artikel der Ausgabe 5/2021

Pneumo News 5/2021 Zur Ausgabe

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH

Passend zum Thema

ANZEIGE

COPD und nicht-invasive Behandlungsmethoden

Content Hub

Nicht-medikamentöse Behandlungsmethoden wie die nicht-invasive Beatmung (NIV) können die Leistungsfähigkeit und Lebensqualität von COPD-Patienten erheblich verbessern und das Sterberisiko senken. Die NIV-Therapie zur Behandlung von fortgeschrittener COPD hat Eingang in die neuen S2k-Leitlinien zur COPD-Therapie gefunden.

ResMed Germany Inc.
ANZEIGE

Geringere Therapieabbruchquoten durch digitale Therapiebegleitung

Ärzte profitieren von digitaler Therapiebegleitung ihrer NIV-Patienten durch einen verlässlichen Partner, weil diese sich besser versorgt fühlen und die Therapie weniger häufig abbrechen. Das entlastet das Gesundheitssystem und schwer Erkrankte gewinnen Lebensqualität.

ANZEIGE

Auch für ältere Patienten empfiehlt sich nicht-invasive Langzeitbeatmung

Nicht-invasive Beatmung ist für Menschen mit chronisch hyperkapnisch respiratorischer Insuffizienz eine bewährte Therapie. Eine Schweizer Studie untersuchte die Auswirkungen der Beatmung auf über 75-Jährige und belegt nun deren Wirksamkeit.